Home › Funds › JOHNSON & JOHNSON › RAPP
JOHNSON & JOHNSON position in RAPP
RAPPORT THERAPEUTICS INC · Health Care
JOHNSON & JOHNSON reported holding 1,784,517 shares of RAPP (RAPPORT THERAPEUTICS INC) in its Q3 2026 13F filing — a position valued at US$60.0M, representing 7.87% of its reported portfolio and ranking #4 among its reported holdings. JOHNSON & JOHNSON has disclosed RAPP holdings in 10 of the last 10 reported quarters, going back to Q2 2024.
Last updated: 2026-11-13 · Source: SEC EDGAR Form 13F-HR
How JOHNSON & JOHNSON's RAPP position evolved
JOHNSON & JOHNSON first disclosed a stake in RAPP in Q2 2024 at 2,498,051 shares (US$58.1M). The position peaked in Q2 2026 at 1,784,517 shares, worth US$74.4M. Across 10 filings, JOHNSON & JOHNSON increased the stake 0 time(s), trimmed it 1 time(s) and left it unchanged 8 time(s). The most recent filing (Q3 2026) shows 1,784,517 shares valued at US$60.0M. Notable position changes include a 29% trim in Q3 2025 (shares rose 2% over the following quarter).
Quarter by quarter
| Quarter | Shares | Value | Change |
|---|---|---|---|
| Q2 2024 | 2.50M | $58.10M | New |
| Q3 2024 | 2.50M | $51.16M | Hold |
| Q4 2024 | 2.50M | $44.32M | Hold |
| Q1 2025 | 2.50M | $25.06M | Hold |
| Q2 2025 | 2.50M | $28.55M | Hold |
| Q3 2025 | 1.78M | $53.00M | Reduce |
| Q4 2025 | 1.78M | $54.14M | Hold |
| Q1 2026 | 1.78M | $55.84M | Hold |
| Q2 2026 | 1.78M | $74.36M | Hold |
| Q3 2026 | 1.78M | $59.96M | Hold |
Dots on the line are colored by change type; missing quarters mean no position was reported.
About RAPP and 13F data
RAPP (RAPPORT THERAPEUTICS INC) is a Health Care company. 61 other funds we track also report a position in RAPP — the largest reported positions include TRV GP V, LLC (US$261.7M), ARCH Venture Management, LLC (US$155.4M), Cormorant Asset Management, LP (US$110.7M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.
Other funds holding RAPP
- TRV GP V, LLC 6.28M sh · $261.71M · Q2 2026
- ARCH Venture Management, LLC 3.73M sh · $155.38M · Q2 2026
- Cormorant Asset Management, LP 2.66M sh · $110.74M · Q2 2026
- Sofinnova Investments, Inc. 1.90M sh · $79.36M · Q2 2026
- BAKER BROS. ADVISORS LP 1.55M sh · $64.47M · Q2 2026
- TRV GP VI, LLC 969.22K sh · $40.39M · Q2 2026
- PERCEPTIVE ADVISORS LLC 773.34K sh · $32.23M · Q2 2026
- Vestal Point Capital, LP 730.00K sh · $30.42M · Q2 2026
- Siren, L.L.C. 641.47K sh · $21.55M · Q3 2026
- Sio Capital Management, LLC 307.66K sh · $12.82M · Q2 2026
- Burkehill Global Management, LP 250.00K sh · $10.42M · Q2 2026
- Artia Global Partners LP 138.51K sh · $5.77M · Q2 2026
More on JOHNSON & JOHNSON
FAQ
How long has JOHNSON & JOHNSON held RAPP?
JOHNSON & JOHNSON has disclosed RAPP holdings in 10 of the last 10 reported quarters, going back to Q2 2024.
What is JOHNSON & JOHNSON's current position in RAPP?
As of Q3 2026, JOHNSON & JOHNSON holds 1.78M shares of RAPP (RAPPORT THERAPEUTICS INC), valued at $59.96M, representing 7.87% of its reported portfolio and ranking #4.
Has JOHNSON & JOHNSON been buying or selling RAPP?
In the latest 13F filing (Q3 2026), JOHNSON & JOHNSON held unchanged its position in RAPP. The position peaked in Q2 2026 at 1.78M shares.
Which other funds hold RAPP?
Other major institutional holders of RAPP include TRV GP V, LLC, ARCH Venture Management, LLC, Cormorant Asset Management, LP, among 61 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.